

(10) International Publication Number  
**WO 2016/022464 A1**(43) International Publication Date  
11 February 2016 (11.02.2016)

## (51) International Patent Classification:

A61K 31/7068 (2006.01) A61K 31/519 (2006.01)  
A61K 31/4184 (2006.01) A61K 31/166 (2006.01)  
A61K 31/675 (2006.01) A61K 31/41 (2006.01)  
A61K 31/513 (2006.01) A61K 38/21 (2006.01)  
A61K 31/506 (2006.01) A61K 38/16 (2006.01)  
A61K 31/437 (2006.01) A61K 39/155 (2006.01)  
A61K 31/4709 (2006.01) A61K 39/42 (2006.01)  
A61K 31/4188 (2006.01) A61P 31/14 (2006.01)  
A61K 31/517 (2006.01) A61P 11/00 (2006.01)

## (21) International Application Number:

PCT/US2015/043402

## (22) International Filing Date:

3 August 2015 (03.08.2015)

## (25) Filing Language:

English

## (26) Publication Language:

English

## (30) Priority Data:

62/033,551 5 August 2014 (05.08.2014) US  
62/060,445 6 October 2014 (06.10.2014) US  
62/182,913 22 June 2015 (22.06.2015) US

(71) Applicant: **ALIOS BIOPHARMA, INC.** [US/US]; 260 E. Grand Avenue, 2nd Floor, South San Francisco, CA 94080 (US).(72) Inventors: **BLATT, Lawrence, M.**; 260 E. Grand Avenue, 2nd Floor, South San Francisco, CA 94080 (US). **BEI-**

**GELMAN, Leonid**; 260 E. Grand Avenue, 2nd Floor, South San Francisco, CA 94080 (US). **SMITH, David, Bernard**; 260 E. Grand Avenue, 2nd Floor, South San Francisco, CA 94080 (US). **WANG, Guangyi**; 260 E. Grand Avenue, 2nd Floor, South San Francisco, CA 94080 (US).

(74) Agent: **MILLER, Kimberly, J.**; Knobbe Martens Olson & Bear, LLP, 2040 Main Street, 14th Floor, Irvine, CA 92614 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK,

[Continued on next page]

(54) Title: COMBINATION THERAPY FOR TREATING A PARAMYXOVIRUS

Figure 1

| Name or CAS No.    | IUPAC Name                                                                                       | Structure |
|--------------------|--------------------------------------------------------------------------------------------------|-----------|
| BMS-433771         | 1-cyclopropyl-3-[[1-(4-hydroxybutyl)benzimidazol-2-yl]methyl]imidazo[4,5-c]pyridin-2-one         |           |
| VP-14637 (MDI-637) | 5,5'-bis[1-((5-amino-1H-tetrazol-2-yl)methyl)-2,2',4'-methyldiynyl]biphenyl                      |           |
| JNJ-24C9066        | 2-[[2-[1-(2-aminoethyl)-1-piperidinyl]amino]-4-methyl-1H-benzimidazol-1-yl]-5-methyl-3-pyridinol |           |

(57) Abstract: Disclosed herein are a combination of compounds and methods of using the combination compounds for ameliorating, treating and/or preventing a paramyxovirus viral infection.



SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

**Published:**

— with international search report (Art. 21(3))

— with sequence listing part of description (Rule 5.2(a))

**Declarations under Rule 4.17:**

— as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))